Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Fcpm Iii Services B.V.

Fcpm Iii Services B.V. lowered its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 18.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,970,668 shares of the company's stock after selling 895,781 shares during the quarter. Replimune Group accounts for about 8.2% of Fcpm Iii Services B.V.'s investment portfolio, making the stock its 5th biggest holding. Fcpm Iii Services B.V. owned 5.80% of Replimune Group worth $48,085,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of REPL. D. E. Shaw & Co. Inc. grew its position in shares of Replimune Group by 12.1% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 972,575 shares of the company's stock worth $11,778,000 after purchasing an additional 104,892 shares in the last quarter. Deutsche Bank AG grew its position in shares of Replimune Group by 4.8% during the fourth quarter. Deutsche Bank AG now owns 561,561 shares of the company's stock worth $6,801,000 after purchasing an additional 25,921 shares in the last quarter. Crestline Management LP purchased a new stake in shares of Replimune Group during the fourth quarter worth about $2,085,000. Algert Global LLC grew its position in shares of Replimune Group by 7.1% during the fourth quarter. Algert Global LLC now owns 45,820 shares of the company's stock worth $555,000 after purchasing an additional 3,057 shares in the last quarter. Finally, Boxer Capital Management LLC purchased a new stake in shares of Replimune Group during the fourth quarter worth about $21,754,000. Hedge funds and other institutional investors own 92.53% of the company's stock.

Replimune Group Stock Down 5.9%

Shares of NASDAQ:REPL traded down $0.44 on Wednesday, reaching $6.97. The company had a trading volume of 338,792 shares, compared to its average volume of 897,737. Replimune Group, Inc. has a 52-week low of $4.92 and a 52-week high of $17.00. The firm's 50 day simple moving average is $9.27 and its 200-day simple moving average is $11.45. The firm has a market capitalization of $536.79 million, a PE ratio of -2.27 and a beta of 0.68. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). As a group, analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

REPL has been the subject of several research analyst reports. JPMorgan Chase & Co. raised their price target on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. HC Wainwright raised their price target on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Finally, BMO Capital Markets raised their price objective on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a report on Wednesday, January 22nd. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $19.43.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.